- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05829603
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects (DHTP)
November 1, 2023 updated by: Reconnect Labs
Single-blind, Randomized, Two-arm, Dose-response Study of DMT and Harmine in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Participants will undergo a series of six study days with varying doses of DMT and Harmine.
The intervention is embedded in controlled environment and continuous psychological support.
Pharmacokinetic and pharmacodynamic assessments are obtained over the course of 24 hours on each study visit to estimate dose-exposure relationship and drug-drug-interaction.
Additionally, the occurrence of adverse events will be closely monitored throughout the whole study.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robin von Rotz, MSc
- Phone Number: +41797990831
- Email: robin@reconnect-labs.com
Study Locations
-
-
ZH
-
Zürich, ZH, Switzerland, 8032
- University Hospital of Psychiatry Zurich
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Willing and capable to give informed consent for the participation in the study after it has been thoroughly explained
- Willing to refrain from drinking alcohol one day before testing days and caffeinated drinks at the testing days and from consuming psychoactive substances or other medications for 2 weeks before testing days and for the duration of the study
- Already experienced with psychedelic substances (at least 5 prior experiences - microdoses do not count)
- Able and willing to comply with all study requirements
- Informed consent form was signed
- Good knowledge of the German language
- Participant informs study physicians / project scientists about simultaneous treatment or therapy with other physicians and about current intake of psychotropic substances or medication
- Women of childbearing potential are required to use effective, established contraception, such as oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
Exclusion Criteria:
- Previous significant adverse response to a hallucinogenic drug
- Participation in another study where pharmaceutical compounds will be given
- Presence of Axis I affective, anxiety, or dissociative disorders
- Present or antecedent diagnosis of bipolar disorder (I, II, not otherwise specified), schizophrenia, schizoaffective disorder, psychosis, or other disorders from the psychotic spectrum
- First-degree relatives with present or antecedent schizophrenia, schizoaffective disorder, or bipolar disorder type I
- History of head trauma, seizures, cancer, or cerebrovascular accidents
- Recent cardiac or brain surgery
- Current addiction of medication or psychotropic substances (including nicotine addiction) according to SCID I criteria
- Presence of major internal or neurological disorders (including sepsis, pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery migraine)
- Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency, myocardical infarction, coronary spastic angina)
- Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe arteriosclerosis, thrombophlebitis, Raynaud's disease)
- Cerebrovascular disease (e.g. stroke, intracranial bleeding / hemorrhage, intracranial aneurysm)
- Serious abnormalities in ECG or blood count/chemistry
- Liver or renal or pulmonary disease
- Pregnant or breastfeeding women (a urine pregnancy test will be done for all women capable of bearing children), occurrence of premenstrual dysphoric disorder (PMDD)
- Current use of medications with significant interaction potential with MAOI (e.g. antidepressants, antipsychotics, psychostimulants, dopaminergic/serotonergic agents, anticonvulsants)
- high risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g. evidence of serious personality disorder, serious current stressors, lack of social support)
Optional wearable data collection (pilot and main study):
Additional inclusion criterion for health data collection sub-cohort using TeleWear and accompanying wearable: possession of a smartphone capable of running the latest version of the TeleWear application and Withings® HealthMate application.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence A
Six varying doses of a fixed-combination of Dimethyltryptamin (DMT) and harmine
|
Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
Other Names:
|
Experimental: Sequence B
Six varying doses of a fixed-combination of Dimethyltryptamin (DMT) and harmine
|
Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameter "Cmax"
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in Cmax of several doses of combined DMT & Harmine
|
Changes from baseline to study days 1,2,3,4,5,6
|
Pharmacokinetic parameter "Area under the curve (AUC)"
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in AUC of several doses of combined DMT & Harmine
|
Changes from baseline to study days 1,2,3,4,5,6
|
Pharmacokinetic parameter "T1/2"
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in T1/2 of several doses of combined DMT & Harmine
|
Changes from baseline to study days 1,2,3,4,5,6
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: On study days 1,2,3,4,5,6
|
Dose-dependent changes in incidence of adverse drug reactions
|
On study days 1,2,3,4,5,6
|
Blood count (Lab biochemistry)
Time Frame: Changes from baseline to End of Study, an average of 6 weeks
|
Changes from baseline in blood count
|
Changes from baseline to End of Study, an average of 6 weeks
|
Clinical chemistry (Lab biochemistry)
Time Frame: Changes from baseline to End of Study, an average of 6 weeks
|
Changes from baseline in any clinical chemistry parameter with potential clinical relevance.
|
Changes from baseline to End of Study, an average of 6 weeks
|
Blood coagulation (Lab biochemistry)
Time Frame: Changes from baseline to End of Study, an average of 6 weeks
|
Changes from baseline in blood coagulation
|
Changes from baseline to End of Study, an average of 6 weeks
|
QT interval (12-lead Electrocardiogram [ECG])
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes of QT intervals assessed by clinical 12-lead ECG)
|
Changes from baseline to study days 1,2,3,4,5,6
|
Blood pressure
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in systolic and diastolic blood pressure
|
Changes from baseline to study days 1,2,3,4,5,6
|
Heart rate
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in heart-rate
|
Changes from baseline to study days 1,2,3,4,5,6
|
Temperature
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in body temperature (in °C)
|
Changes from baseline to study days 1,2,3,4,5,6
|
Genotyping
Time Frame: At screening
|
Collection of saliva-samples to determine genetic polymorphisms
|
At screening
|
Subjective effects
Time Frame: Changes from baseline to study days 1,2,3,4,5,6
|
Dose-dependent changes in trajectories of subjective effects
|
Changes from baseline to study days 1,2,3,4,5,6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aliveness - Behavioral Task
Time Frame: Changes from baseline to study days 1,2,3
|
Validated instrument developed to assess dose-dependent changes in perceived aliveness.
|
Changes from baseline to study days 1,2,3
|
Heart-rate-Variability, Physical Activity, Sleep Patterns
Time Frame: Continuously throughout the study until End of Study, an average of 6 weeks
|
Wearable device for continuous sensor assessments
|
Continuously throughout the study until End of Study, an average of 6 weeks
|
Heart-rate-variability
Time Frame: Continuously throughout the study until End of Study, an average of 6 weeks
|
Occurence of dose-dependent changes in heart-rate-variability assessed by a wearable device
|
Continuously throughout the study until End of Study, an average of 6 weeks
|
Physical Activity
Time Frame: Continuously throughout the study until End of Study, an average of 6 weeks
|
Occurence of dose-dependent changes in physical activity assessed by a wearable device
|
Continuously throughout the study until End of Study, an average of 6 weeks
|
Sleep Patterns
Time Frame: Continuously throughout the study until End of Study, an average of 6 weeks
|
Occurence of dose-dependent changes in sleep patterns assessed by a wearable device
|
Continuously throughout the study until End of Study, an average of 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Erich Seifritz, Prof, University Hospital of Psychiatry Zurich
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2023
Primary Completion (Actual)
September 17, 2023
Study Completion (Actual)
October 17, 2023
Study Registration Dates
First Submitted
March 3, 2023
First Submitted That Met QC Criteria
April 13, 2023
First Posted (Actual)
April 25, 2023
Study Record Updates
Last Update Posted (Actual)
November 2, 2023
Last Update Submitted That Met QC Criteria
November 1, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DMT-HAR-TOM-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan available to date.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Dimethyltryptamin (DMT) & Harmine
-
Psychiatric University Hospital, ZurichUniversity of BaselCompletedEmotions | Mood | Cognitive Function 1, Social | EmpathySwitzerland
-
Milan ScheideggerUniversity Medical Center FreiburgCompleted
-
Insel Gruppe AG, University Hospital BernPsychiatric University Hospital, ZurichRecruitingNeuropharmacological Investigation of Ayahuasca Constituents DMT and HarmineSwitzerland
-
Rennes University HospitalRecruiting
-
James MurroughNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
The University of Hong KongTung Wah Group of HospitalsCompleted
-
Amasya UniversityCompletedSchizophrenia | Disabilities Mental | Negative Symptoms in Schizophrenia | Dance TherapyTurkey
-
Yale UniversityActive, not recruitingDepression | Major Depressive DisorderUnited States
-
Centre de Recherche de l'Institut Universitaire...Completed
-
Max NieuwdorpNot yet recruitingUpper Respiratory Tract InfectionNetherlands